Michael Recht, M.D., Ph.D
- click here
- 503 346-0644
Adjunct Associate Professor
Dr. Recht serves as the regional director for the federally-funded Hemophilia Treatment Centers in the states of Oregon, Washington, Idaho, and Alaska. He is also medical director of the Oregon Hemophilia Treatment Center. Before joining the faculty of OHSU in September 2007, Dr. Recht had been director of the hematology service and Hemophilia Center at Phoenix Children's Hospital for 10 years. His primary clinical focus is the treatment of children and adolescents affected by non-malignant blood conditions, particularly bleeding and clotting disorders. As a member of the Division of Pediatric Hematology/Oncology, he contributes to the care of patients with cancer and blood disorders at Doernbecher Children's Hospital and directs the Pediatric Hematology Consult Service.
Dr. Recht has actively participated in over 30 clinical research trials testing new treatments for children with bleeding and clotting disorders. In addition, he is currently engaged in research studying the psychological and educational impact of chronic illness in childhood. After growing up in Milwaukee, Wisconsin, Dr. Recht received his BS in psychology, his PhD in human cancer biology, and his MD, all at the University of Wisconsin. He completed his residency and fellowship training at Yale University School of Medicine.
Summary of Current Research
Pediatric hematology and oncology concentrating on non-malignant disorders of the blood, in particular conditions of bleeding and clotting
"A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A,"
"Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates,"
"Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening,"
"Results from a large multinational clinical trial (guardianâ„¢1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: Safety and efficacy,"
"The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption,"